Table 1.

Patient characteristics (N = 50)

CharacteristicsValues
Age ≥75 y, n (%) 26 (52) 
Median age (range), y 75 (66-84) 
Male, n (%) 29 (58) 
ECOG status, n (%)  
 0 to 1 43 (86) 
 2 7 (14) 
AML type, n (%)  
 De novo 33 (66) 
 Secondary 12 (24) 
  MDS 10 (20) 
  MPN 2 (4) 
 Therapy-related 5 (10) 
AML FAB classification, n (%)  
 M0 5 (10) 
 M1 7 (14) 
 M2 19 (38) 
 M4 8 (16) 
 M5 3 (6) 
 M6 2 (4) 
 Unknown 6 (12) 
Cytogenetic risk group, n (%)  
 Intermediate 27 (54) 
  Cytogenetically normal 21 (42) 
  Cytogenetically abnormal 6 (12) 
 High 21 (42) 
Median peripheral blood blasts (range), % 2 (0-77) 
Median BM blasts (range), % 40 (20-89) 
Median hemoglobin (range), g/dL 9.3 (6.5-15.3) 
Median platelets (range), ×109/L 45.5 (9-639) 
Median white blood cell count (range), ×109/L 2.6 (0.8-29.6) 
Median ANC (range), ×109/L 0.58 (0-6.8) 
Median creatinine (range), mg/dL 0.9 (0.5-1.6) 
Median bilirubin (range), mg/dL 0.6 (0.2-5) 
CharacteristicsValues
Age ≥75 y, n (%) 26 (52) 
Median age (range), y 75 (66-84) 
Male, n (%) 29 (58) 
ECOG status, n (%)  
 0 to 1 43 (86) 
 2 7 (14) 
AML type, n (%)  
 De novo 33 (66) 
 Secondary 12 (24) 
  MDS 10 (20) 
  MPN 2 (4) 
 Therapy-related 5 (10) 
AML FAB classification, n (%)  
 M0 5 (10) 
 M1 7 (14) 
 M2 19 (38) 
 M4 8 (16) 
 M5 3 (6) 
 M6 2 (4) 
 Unknown 6 (12) 
Cytogenetic risk group, n (%)  
 Intermediate 27 (54) 
  Cytogenetically normal 21 (42) 
  Cytogenetically abnormal 6 (12) 
 High 21 (42) 
Median peripheral blood blasts (range), % 2 (0-77) 
Median BM blasts (range), % 40 (20-89) 
Median hemoglobin (range), g/dL 9.3 (6.5-15.3) 
Median platelets (range), ×109/L 45.5 (9-639) 
Median white blood cell count (range), ×109/L 2.6 (0.8-29.6) 
Median ANC (range), ×109/L 0.58 (0-6.8) 
Median creatinine (range), mg/dL 0.9 (0.5-1.6) 
Median bilirubin (range), mg/dL 0.6 (0.2-5) 

ANC, absolute neutrophil count; FAB, French-American-British; MPN, myeloproliferative neoplasm.

Close Modal

or Create an Account

Close Modal
Close Modal